The Olga and Lev Leviev Heart Center, Sheba Medical Center, Ramat Gan, Israel.
The Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
Clin Transplant. 2018 Oct;32(10):e13389. doi: 10.1111/ctr.13389. Epub 2018 Sep 27.
The impact of donor-recipient ethnic matching on heart transplantation (HT) has been poorly studied with inconclusive results. We aimed to investigate the impact of ethnic matching on HT outcomes in Israeli multiethnic patients.
The study comprised 168 patients who underwent HT from 1990-2017. Patients and their donors were ethnically categorized to Jews and Arabs. Primary end points were all-cause in-hospital and late mortality; secondary end points included primary graft dysfunction (PGD), rejections, and vasculopathy.
Donor-recipient ethnic matching was found in 111 patients, while 57 were ethnically mismatched. Baseline characteristics were similar in both groups. Ethnic mismatching was associated with >7-fold (P = 0.018) increased risk for in-hospital mortality and >8-fold (P < 0.001) increased risk for PGD. Kaplan-Meier survival analysis showed that overall survival at 10 years was significantly higher among matched patients (73% vs 43%, log-rank P < 0.001). Multivariate analysis showed that ethnic mismatching was associated with an approximately fourfold higher risk for death (P < 0.01). These findings were validated by propensity score analysis. The ethnic mismatched group experienced significantly higher rejection rates compared with the matched group with lower survival free of rejections (log-rank P = 0.029). No differences in vasculopathy were found.
Donor-recipient ethnic mismatch is an important independent predictor of early- and long-term outcomes following HT, and is associated with increased risk for PGD, rejections, and mortality. These findings will help to design tailored treatment protocols leading to improved outcomes after HT.
供受者种族匹配对心脏移植(HT)的影响研究甚少,结果尚无定论。我们旨在研究以色列多民族患者中种族匹配对 HT 结局的影响。
本研究纳入 1990 年至 2017 年间接受 HT 的 168 例患者。患者及其供者按犹太人(Jews)和阿拉伯人(Arabs)进行种族分类。主要终点为全因住院和晚期死亡率;次要终点包括原发性移植物功能障碍(PGD)、排斥反应和血管病变。
发现 111 例患者供受者种族匹配,57 例不匹配。两组的基线特征相似。种族不匹配与住院死亡率增加 7 倍以上(P=0.018)和 PGD 风险增加 8 倍以上(P<0.001)相关。Kaplan-Meier 生存分析显示,匹配患者的 10 年总生存率显著更高(73%比 43%,对数秩 P<0.001)。多变量分析显示,种族不匹配与死亡风险增加约 4 倍相关(P<0.01)。倾向评分分析验证了这些发现。与匹配组相比,不匹配组排斥反应发生率更高,排斥反应无生存率更高(对数秩 P=0.029)。两组血管病变无差异。
供受者种族不匹配是 HT 后早期和长期结局的重要独立预测因素,与 PGD、排斥反应和死亡率增加相关。这些发现将有助于设计量身定制的治疗方案,以改善 HT 后的结局。